Close Menu

IVF

Reproductive Medicine Associates of New Jersey is currently enrolling patients in a clinical validation trial of targeted next-generation sequencing-based preimplantation genetic testing to aid in the selection of embryos for transfer as part of in vitro fertilization.

This article was originally published on Jan. 29.
Microarrays are still a growing business for Illumina.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

Oxford Gene Technology this week launched a new microarray that can be used to screen embryos for chromosomal abnormalities prior to implantation during an in vitro fertilization cycle.

This story was originally posted on March 7

Illumina's acquisition of BlueGnome has provided a boost for its array business.

This story was originally posted on Oct. 24

Good Start Genetics has expanded the disorders it covers in its sequencing-based preconception carrier screening service to 23 after launching a more limited panel in April.

This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.

Using arrays to screen embryos during an in vitro fertilization cycle can improve pregnancy rates, according to a new study.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.